Narcolepsy Therapeutics: Global Strategic Business Report

Global Narcolepsy Therapeutics Market to Reach $3.6 Billion by 2030

The global market for Narcolepsy Therapeutics estimated at US$2 Billion in the year 2022, is projected to reach a revised size of US$3.6 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2022-2030. Narcolepsy with Cataplexy, one of the segments analyzed in the report, is projected to record a 7% CAGR and reach US$1.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Narcolepsy without Cataplexy segment is readjusted to a revised 8.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $558.1 Million, While China is Forecast to Grow at 11.7% CAGR

The Narcolepsy Therapeutics market in the U.S. is estimated at US$558.1 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$833.8 Million by the year 2030 trailing a CAGR of 11.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.9% and 7.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$503.2 Million by the year 2030.

Select Competitors (Total 14 Featured) -

• Arena Pharmaceuticals, Inc.
• BioProjet Pharma
• Graymark Healthcare, Inc.
• Jazz Pharmaceuticals PLC
• Ligand Pharmaceuticals, Inc.
• Shionogi, Inc.
• Shire PLC
• Teva Pharmaceutical Industries Ltd.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year